Allspring Global Investments Holdings LLC Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Allspring Global Investments Holdings LLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 2,166.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,264 shares of the company's stock after purchasing an additional 25,105 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.06% of Janux Therapeutics worth $282,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in shares of Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company's stock worth $29,000 after acquiring an additional 2,685 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of Janux Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company's stock worth $152,000 after acquiring an additional 3,602 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $57,000. SG Americas Securities LLC bought a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $100,000. Finally, Old Well Partners LLC bought a new position in shares of Janux Therapeutics during the 3rd quarter worth approximately $104,000. 75.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JANX. BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They set a "buy" rating and a $62.00 target price for the company. Cantor Fitzgerald initiated coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an "overweight" rating and a $100.00 price target for the company. Bank of America boosted their price target on Janux Therapeutics from $24.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, March 13th. Wedbush restated an "outperform" rating and issued a $53.00 price target on shares of Janux Therapeutics in a research note on Monday, March 11th. Finally, Jonestrading initiated coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They issued a "buy" rating and a $70.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $61.33.

Janux Therapeutics Trading Up 0.6 %

NASDAQ JANX traded up $0.29 during midday trading on Friday, hitting $47.39. The company had a trading volume of 573,989 shares, compared to its average volume of 824,306. The company has a market capitalization of $2.45 billion, a PE ratio of -35.37 and a beta of 4.18. The firm has a 50-day moving average price of $39.14 and a 200-day moving average price of $19.57. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $58.69.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.12. The firm had revenue of $2.46 million during the quarter, compared to analysts' expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.41 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.